Enavermotide
Enavermotide (UCP2) is a research-grade small molecule agent developed for active cancer immunotherapy. It functions as a UCP2 inhibitor, applied in pre-clinical oncology studies to investigate metabolic reprogramming of tumors in both in vitro and in vivo experimental models.
Product Specifications
Molecular Weight
1767.04
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog